Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials

AbstractAdjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.